Head to Head Comparison: OpGen (OPGN) versus NewLink Genetics (NLNK)

OpGen (NASDAQ: OPGN) and NewLink Genetics (NASDAQ:NLNK) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, valuation, institutional ownership, earnings and dividends.

Profitability

This table compares OpGen and NewLink Genetics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
OpGen -533.47% -1,289.51% -234.78%
NewLink Genetics -229.19% -63.39% -47.83%

Valuation & Earnings

This table compares OpGen and NewLink Genetics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
OpGen $4.03 million 2.94 -$19.16 million ($0.51) -0.41
NewLink Genetics $35.77 million 8.76 -$85.15 million ($2.44) -3.47

OpGen has higher earnings, but lower revenue than NewLink Genetics. NewLink Genetics is trading at a lower price-to-earnings ratio than OpGen, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

11.8% of OpGen shares are held by institutional investors. Comparatively, 52.6% of NewLink Genetics shares are held by institutional investors. 17.4% of OpGen shares are held by insiders. Comparatively, 13.7% of NewLink Genetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings for OpGen and NewLink Genetics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OpGen 0 0 2 0 3.00
NewLink Genetics 0 0 6 0 3.00

OpGen presently has a consensus price target of $1.00, indicating a potential upside of 376.19%. NewLink Genetics has a consensus price target of $25.67, indicating a potential upside of 203.57%. Given OpGen’s higher probable upside, research analysts clearly believe OpGen is more favorable than NewLink Genetics.

Summary

NewLink Genetics beats OpGen on 7 of the 12 factors compared between the two stocks.

OpGen Company Profile

OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company’s high-resolution DNA tests are marketed under the Acuitas trade name.

NewLink Genetics Company Profile

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer.

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit